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Christopher Duplessis1* , Michael Gregory1, Kenneth Frey1, Matthew Bell1, Luu Truong1, Kevin Schully1,
James Lawler1, Raymond J. Langley2, Stephen F. Kingsmore3, Christopher W. Woods4,5,6, Emanuel P. Rivers7,
Anja K. Jaehne7, Eugenia B. Quackenbush8, Vance G. Fowler4, Ephraim L. Tsalik4,5,9 and Danielle Clark1
Abstract
Background: Sepsis biomarker panels that provide diagnostic and prognostic discrimination in sepsis patients
would be transformative to patient care. We assessed the mortality prediction and diagnostic discriminatory
accuracy of two biomarkers reflective of cell death (apoptosis), circulating cell-free DNA (cfDNA), and nucleosomes.
Methods: The cfDNA and nucleosome levels were assayed in plasma samples acquired in patients admitted from
four emergency departments with suspected sepsis. Subjects with non-infectious systemic inflammatory response
syndrome (SIRS) served as controls. Samples were acquired at enrollment (T0) and 24 h later (T24). We assessed
diagnostic (differentiating SIRS from sepsis) and prognostic (28-day mortality) predictive power. Models
incorporating procalcitonin (diagnostic prediction) and APACHE II scores (mortality prediction) were generated.
Results: Two hundred three subjects were included (107 provided procalcitonin measurements). Four subjects
exhibited uncomplicated sepsis, 127 severe sepsis, 35 septic shock, and 24 had non-infectious SIRS. There were
190-survivors and 13 non-survivors. Mortality prediction models using cfDNA, nucleosomes, or APACHEII yielded
AUC values of 0.61, 0.75, and 0.81, respectively. A model combining nucleosomes with the APACHE II score
improved the AUC to 0.84. Diagnostic models distinguishing sepsis from SIRS using procalcitonin, cfDNA(T0), or
nucleosomes(T0) yielded AUC values of 0.64, 0.65, and 0.63, respectively. The three parameter model yielded an
AUC of 0.74.
Conclusions: To our knowledge, this is the first head-to-head comparison of cfDNA and nucleosomes in
diagnosing sepsis and predicting sepsis-related mortality. Both cfDNA and nucleosome concentrations
demonstrated a modest ability to distinguish sepsis survivors and non-survivors and provided additive diagnostic
predictive accuracy in differentiating sepsis from non-infectious SIRS when integrated into a diagnostic prediction
model including PCT and APACHE II. A sepsis biomarker strategy incorporating measures of the apoptotic pathway
may serve as an important component of a sepsis diagnostic and mortality prediction tool.
Keywords: Cell-free DNA, Nucleosomes, Severe Sepsis, Procalcitonin, Sepsis prognostication, Sepsis diagnosis
Background
Sepsis remains a leading cause of mortality globally. Des-
pite concerted research into improving treatment and
survival, few novel efficacious therapies have been iden-
tified. Sepsis contributes up to 750,000 hospitalizations
annually in the USA, is the most common etiology of
ICU-associated mortality, and incurs 50% mortality rates
in severe cases [1–7]. The pathophysiology of sepsis is
complex, multifactorial, and heterogeneous involving
multiple interdependent pathways (proinflammatory,
anti-inflammatory, regulatory, and coagulation/fibrinoly-
sis) which become dysregulated and uncoordinated [8].
Given the heterogeneity of sepsis, accurate diagnosis,
stratification, and prognosis will require biomarker
panels to capture the evolving and dynamic information
provided by multiple unique and interdependent
cascades [9, 10]. Sepsis biomarker panel candidates may
require representation of (1) multiple non-collinear
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pathways (from a potentially infinite orthogonal space),
(2) counter-regulatory biomarkers (capturing uncoordin-
ated and dysregulated activity), and (3) temporal trends
(“kinetics”) [11]. For example, procalcitonin (PCT) dy-
namics are superior in sepsis prognostication than
isolated measurements [12]. Apoptosis is a process in
which intracellular death programs are activated (pro-
grammed cell death). Apoptotic cells shrink and con-
dense with a collapse of the cytoskeleton accompanied
by dissemblance of the nuclear envelope and leakage of
intact and degraded DNA fragments [3, 13].
The apoptosis pathway is increasingly recognized as
integral to sepsis pathophysiology, and therefore,
representative biomarkers may provide additive discrim-
inatory power in sepsis biomarker panels [3, 13]. Apop-
totic pathway activation increases with sepsis severity
often leading to marked lymphopenia within the initial
24 h [14, 15]. Apoptotic depletion of immune cells can
undermine host immunity by engendering anergy, latent
infection reactivation, and susceptibility to secondary in-
fections [4, 14, 15]. Apoptosis-induced cellular debris in-
creases immunogenic cellular by-products (including
damage-associated molecular patterns (DAMPs)) con-
tributing to immune tolerance and deleterious immune
activation and dysregulation [3, 4, 14–17]. As apoptotic
biomarkers represent the integrated cumulative organ
injury and systemic inflammation portending future tis-
sue damage [13], they may provide independent,
non-collinear (additive) discriminatory predictive power
when combined with traditional biomarkers or the APA-
CHEII score [3, 13, 15, 18]. Extracellular cell-free DNA
(cfDNA) and nucleosome levels both reflect cellular
apoptosis activity and may serve as representative bio-
markers of this pathway [3, 19, 20].
Circulating cfDNA (encompassing nuclear and
mitochondrial-DNA) derives from cellular necrosis, lysis,
apoptosis, and secretion (i.e., neutrophil extracellular
traps (NETs)) [3, 13, 21–23]. Although bacteria may
contribute, it appears to be a minor contributor in infec-
tious syndromes [3]. Nucleosomes are basic units of
DNA packaging stemming from chromatin degradation
by endonucleases during apoptosis or necrosis [24, 25].
Nucleosomes are the basic unit of DNA packaging
whereby DNA is wound around histone core proteins.
Histones represent a class of DAMP molecules, are cyto-
toxic to endothelial and epithelial cells, and contribute
to NETosis, which also directly participates in inflamma-
tion and the response to infection (activating TLR2,
TLR4, and NF-κβ signaling) [1, 26]. In healthy individ-
uals, circulating cfDNA and nucleosome levels are low,
exhibiting short half-lives (15 min) given efficient c-
learance (in the liver) [1, 22]. In illness, levels rise from ex-
cessive cellular injury/death, insufficient clearance, or
decrements in endogenous DNase [1, 15, 24]. Improvement
in detection has fostered studies in many clinical arenas
(cancer, trauma, stroke, myocardial infarction, rheumatoid
arthritis, and sepsis) to assess their utility as discriminative
diagnostic and prognostic biomarkers [3, 15, 17, 20–22, 27].
Furthermore, pilot studies suggest cfDNA and nu-
cleosome concentrations correlate with sepsis sever-
ity [15, 22]. The origins of both cfDNA and
nucleosomes depend on the particular clinical syndrome.
For example, extracellular nucleic acids are plausibly re-
leased from the direct injurious insult sustained in trauma,
or the rapidly dividing tumor cells in cancer. In sepsis, it is
thought these extracellular nucleic acids derive from
hematologic cells (neutrophils and lymphocytes) partici-
pating in the immune response to infection, with
contributions from tissue injury sustained in organ
damage [3, 17, 23]. We are unaware of associations be-
tween cfDNA and nucleosome concentrations with
preceding neutrophil and lymphocyte levels (i.e., immune-
suppressed patients), nor attributable contributions from
the hematological cells vice tissue injury across sepsis se-
verity all warranting future study.
We measured cfDNA and nucleosome levels in ar-
chived plasma samples acquired from the Community
Acquired Pneumonia and Sepsis Outcome Diagnostic
(CAPSOD) study. Our primary objectives were to assess
the diagnostic (differentiating SIRS and sepsis) and prog-
nostic (28-day mortality) performance of both bio-
markers. In this preliminary biomarker discovery effort,
we included PCT and APACHE II score to determine if
apoptotic biomarkers offered independent classification
utility. Specifically, models incorporating procalcitonin
(for diagnostic prediction) and APACHE II scores (for
mortality prediction) were also generated.
Methods
Archived samples from the CAPSOD investigation
In the CAPSOD study (ClinicalTrials.gov NCT00258869),
1152 individuals with suspected community-acquired sep-
sis [≥ 2 Systemic Inflammatory Response Syndrome (SIRS)
criteria presumed due to an infection] were enrolled pro-
spectively in the emergency departments at three urban,
tertiary-care hospitals in the USA (Duke University,
Durham VA Medical Center, and Henry Ford Hospital)
from 2005 to 2009 (Fig. 1). Later, a fourth emergency de-
partment was added (UNC Medical Center) where enroll-
ment occurred in 2010. Some were later adjudicated as
having non-infectious SIRS. Medical history, physical
examination, and acute illness scores (APACHE II) were
recorded at enrollment (T0) and 24 h later (T24). Blood
specimens were acquired at the corresponding
time-points [6].
The primary outcome was survival at day-28, which
along with infectious status was adjudicated by
board-certified clinicians. Definitions that were standard
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at that time were employed for organ dysfunction and
shock [6]. The definitions used for the adjudication
process were based on the 2001 Consensus definition
for sepsis [28]. The investigators pursued proteomics
and metabolomics on patient samples to identify novel
signatures predicting sepsis-associated mortality and
have published a parsimonious set of metabolites exhi-
biting excellent prognostication for sepsis-associated
mortality [6].
We accessed a sub-sample (n = 203) of the enrolled
patients in this effort. Subject selection from the pool of
1152 subjects was first constrained by removing indeter-
minate adjudications where individual subjects could not
be definitively assigned as having sepsis or SIRS. Sample
selection was further constrained by those subjects for
whom an adequate volume of residual plasma remained.
This resulted in 203 evaluable subjects. We did not iden-
tify an introduction of any significant systematic bias im-
posed by the two constraints in this subcohort analyzed
in terms of demographics (age, gender), source of infec-
tion, infectious pathogen, or representation across the
various sepsis categories save for uncomplicated sepsis.
Sample processing was harmonized at all participating
sites with immediate separation of plasma subsequently
frozen at − 20 °C and underwent one freeze-thaw cycle
prior to assaying. This retrospective analysis of previ-
ously acquired specimens was approved by the Naval
Medical Research Center (NMRC) institutional review
board (IRB) as exempt (non-human subjects research)
under protocol NRMC.2014.0008.
Assays
cfDNA
The cfDNA was assayed using SYBR® Gold Nucleic Acid
Gel Stain, (Invitrogen, Paisley, UK) via the fluorometric
method [3]. This assay yields similar cfDNA levels
employing serum or plasma, correlates significantly with
conventional β-globin gene DNA quantification [R2 =
0.9987 (p < 0.0001)], and remains immune to organic
molecular interference when samples are diluted to <
30% [3]. We executed the assay with slight modification
(improving assay resolution). Specifically, SYBR® Gold
was diluted at 1:1000 in dimethyl sulphoxide (DMSO,
Sigma-Aldrich) and then at 1:8 in phosphate-buffered
saline. An eight-point standard curve was created
employing ultrapure salmon sperm DNA (Life
Technologies, Carlsbad, CA, USA) diluted in 2% BSA/
100 mM HEPES from 4 to 0.13 μg/ml [yielding a robust
linear curve (R2 > 0.99) between 0.25 and 4 μg/ml] (cor-
responding to a sample range: 20 to 1.25 μg/ml upon 1:5
dilution in the assay) aligning with 1:5 dilutions (in 2%
BSA/100 mM HEPES) applied to samples and controls
[10 μg/ml and 5 μg/ml (2 μg/ml and 1 μg/ml upon 1:5
dilutions)]. A common plasma control was applied to all
plates to control for plate-to-plate variability. Twenty
microliters of standards, controls, and samples were ap-
plied to black 96-well plates (Greiner Bio-One, Fricken-
hausen, Germany). Diluted SYBR® Gold was added
(80 μl) to each well (final dilution 1:10,000), and fluores-
cence measured with a 96-well fluorometer (Ultra Evolu-
tion; Tecan, Durham, NC, USA) at an emission
wavelength of 535-nm and an excitation wavelength of
485-nm. The low end of our linear curve overlaps the
anticipated upper end of the normal range of healthy
patients (1 μg/ml) which is known to exhibit signifi-
cant intra- and inter-individual variability [3]. The
intra-day CV is 16%, 7.9%, and 4.8% and inter-day CV is
31%, 6.7%, and 8% in the low (383 ng/ml), elevated
(1152 ng/ml), and high DNA range (2735 ng/mL), re-
spectively [3].
Nucleosomes The nucleosomes were quantified using
the Cell Death Detection ELISAPlus kit (Roche Life Sci-
ence, Indianpolis, IN, USA) according to the manufac-
turer’s instructions. This assay employs two murine
antibodies directed at DNA (detection) and histones
Fig. 1 Enrollment flowchart
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(capture). An eight-point standard curve was generated
by twofold standard dilution of purified human nucleo-
somes (Human native nucleosomes; EMD Millipore,
Billerica, MA, USA) in the incubation buffer from the
enzyme-linked immunosorbent assay (ELISA) kit.
Samples (18 uL) were assayed in duplicate. Standards
and samples were applied followed by 80 uL of immu-
noreagent. Plates were incubated at (21 °C) for 2 h while
shaking gently (300 rpm). Plates were decanted and
washed thrice using 250 uL of incubation buffer/well.
ABTS (100 uL) solution was added per well and incu-
bated at room temperature with gentle shaking
(250 rpm) for 15 min. The detection reaction was
stopped with 100 uL of stop solution/well. The optical
density of the wells at 405 nm were read on an Epoch
microplate spectrophotometer (BioTek; Winooski, VT,
USA). Standard curves were fitted to a five-parameter
logistic curve using the GEN5 Data Analysis Software
version 2.01 (BioTek) allowing interpolation for sample
concentrations.
Procalcitonin Procalcitonin (PCT) was measured from
serum samples on a Roche Elecsys 2010 analyzer (Roche
Diagnostics) by electrochemiluminescence or on the
miniVIDAS immunoassay (bioMerieux). When serum
was unavailable, measurements were made by the Phadia
Immunology Reference Laboratory in plasma-EDTA by
immunofluorescence using the BRAHMS PCT sensitive
KRYPTOR (Thermo Fisher Scientific). Replicates were
performed for some paired serum and plasma samples,
revealing equivalence in concentrations. Therefore, all
PCT measurements (ng/ml) were treated equivalently,
regardless of testing platforms.
Statistical analyses
Demographic and clinical data were compared with
chi-squared, Student’s t test, or Wilcoxon rank sum test.
Non-normal data were log-transformed. Spearman’s
rank-order correlation coefficients were calculated to
evaluate correlations between biomarkers and APACHE
II scores. Statistical significance was defined as p < 0.05.
Prediction of 28-day mortality and discrimination be-
tween SIRS and sepsis were performed using logistic re-
gression models. Performance was evaluated using area
under the curve (AUC). All analyses were done with
Stata (version-14).
Results
Study population
This was a nested case-control study focusing on sub-
jects within the CAPSOD cohort. After identifying individ-
uals with residual plasma, we identified 203 subjects with
clinically adjudicated sepsis (n = 179) or non-infectious
SIRS (n = 24) (Table 2). The sepsis group was further
stratified by sepsis severity using definitions available dur-
ing the enrollment period (i.e., before Sepsis-3) and as pre-
viously defined [6]. The cohort was further stratified by
28-day survival. Overall mortality was low (6.4% mirroring
the 4.9% in the full CAPSOD cohort) resulting in 190 sur-
vivors and 13 non-survivors. All the mortality events were
in subjects with sepsis. Although the original investigation
enrolled from four sites, most of our samples were derived
from a single site (Duke). There were no significant differ-
ences in age, gender, or race between survivors and
non-survivors. We did observe a significant difference in
comorbidities. Non-survivors had a higher prevalence of
cirrhosis, chronic kidney disease, and chronic pulmonary
disease. Bacterial pathogens were recovered from 28% of
subjects. Staphylococcus aureus was most common (n =
16) followed by Escherichia coli (n = 10), Klebsiella pneu-
moniae (n = 9), and Streptococcus pneumoniae (n = 7). In-
fluenza A was identified from two patients: one survivor
and one non-survivor (Table 1).
Assessment of significance across sepsis stratifications in
biomarkers (cfDNA, nucleosome, and procalcitonin
concentrations) and APACHE II score (Table 2)
Under the hypothesis that apoptosis is a prominent host
pathway in response to infection, we systematically com-
pared cfDNA and nucleosome concentrations (seeking
significant differences) among patients exhibiting various
categories of sepsis (Table 2). Saliently, the sepsis
severity categories delineated in Table 2 are based on the
maximum severity achieved. Our subsequent analyses
included comparing sepsis as compared to non-
infectious SIRS, sepsis severities (i.e., uncomplicated sep-
sis, severe sepsis, and septic shock), and sepsis survival
outcomes. Moreover, we compared concentrations at the
time of enrollment (T0) and 24 h later (T24). Our
reporting framework will assess cfDNA, followed by
nucleosomes, PCT, and the APACHE II score.
For the cfDNA evaluation, as expected, we observed a
trend toward higher cfDNA concentrations as sepsis se-
verity increased. Specifically, we noted significant differ-
ences (increases) in the mean cfDNA concentrations
between SIRS patients (3.0 μg/ml) when compared to
patients experiencing severe sepsis (3.9 μg/ml; p = 0.02),
septic shock (4.8 μg/ml; p = 0.01), and death (3.9 μg/ml;
p = 0.04). There was a significant difference in the
cfDNA concentrations between subjects experiencing
sepsis vice SIRS (p = 0.009). We did not identify a signifi-
cant difference in the cfDNA levels between survivors
and non-survivors.
With respect to nucleosomes, there were significant
differences observed in the mean nucleosome concentra-
tions between SIRS patients (1.1 μg/ml) when compared
to patients experiencing septic shock (5.5 μg/ml; p =
0.012) and those who died (5.0 μg/ml; p = 0.001). We
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also noted significant differences between patients ex-
periencing severe sepsis (3.0 μg/ml) and death (p =
0.003). There was a significant difference in the nucleo-
some concentrations between subjects experiencing sep-
sis vice SIRS (p = 0.036). We noted a significant
difference in nucleosome concentrations between survi-
vors and non-survivors (p = 0.007).
With respect to PCT, there were significant differences
observed in the mean PCT concentration between
patients experiencing SIRS (7.5 μg/ml) and septic shock
(20.7 μg/ml; p = 0.002). We did observe a significant dec-
rement in PCT levels from SIRS to severe sepsis (6.5 μg/
ml; p < 0.002). There was no significant difference in
PCT concentrations in subjects experiencing sepsis vice
SIRS. There were too few mortality cases with PCT mea-
surements for meaningful interpretation in mortality
prediction models nor to assert differences between sur-
vivors and non-survivors.
The average APACHE II score was significantly lower
in SIRS patients (8.3) when compared to patients experi-
encing septic shock (15.5; p < 0.001) or those who died
(17.5; p < 0.001). APACHE II was also lower in patients
experiencing severe sepsis (9.0) compared to septic
shock and death (p < 0.001 for both comparisons). The
APACHE II score was significantly elevated in subjects
experiencing sepsis vice SIRS (p = 0.044). The APACHE
II score was significantly higher in non-survivors vice
survivors (p < 0.001).
Finally, we identified no significant difference in the
cfDNA biomarker concentrations measured at T0 and
T24. Unlike the cfDNA levels, we did identify significant
elevations in the nucleosome levels from T0 to T24, ac-
companied by increased variability at T24 relative to
cfDNA in all groups (SIRS, death, and all severities of
sepsis). Given the increased variability and the fact that
there was no difference in the predictive accuracy when
exploiting nucleosomes at T0 vice T24, we present the
concentrations for nucleosomes (and all biomarkers) at
T0 in Table 2 and all analyses assessing predictive accur-
acy utilizes values at T0 (see Figs. 2 and 3).
Table 1 Demographic table
Characteristic Died
(N = 13)
Survived
(N = 190)
Age [median (IQR)] 64 (53–76) 54 (40–67)
Male [n (%)] 8 (62) 107 (56)
Caucasian [n (%)] 11 (85) 116 (61)
Comorbidities [n (%)] + 9 (69)* 67 (35)*
CAP [n (%)] 7 (54)* 29 (15)*
Pathogen [n (%)]
Unidentified 7 (54) 139 (73)
Staphylococcus aureus 1 (8) 15 (8)
Escherichia coli 1 (8) 9 (5)
Klebsiella pneumoniae 0 (0) 9 (5)
Streptococcus pneumoniae 1 (8) 6 (3)
Other 3 (23) 12 (6)
*Significant difference between survivors and non-survivors (p < 0.05)
+Comorbidities include liver failure, heart failure, renal failure, neoplasm,
chronic lung disease, immunosuppression, neutropenia, HIV, hemodialysis,
corticosteroid use, or chemotherapy
CAP community-acquired pneumonia
Table 2 Mean biomarker concentrations and APACHE II scores at enrollment (T0) stratified by sepsis categories (maximum sepsis
severity achieved)
cfDNA (μg/ml)
Mean (SD)6
Nucleosome (μg/ml)
Mean (SD)7
APACHE II
Mean (SD)9
5,8PCT (ng/ml)
Mean (SD)
Non-infectious SIRS1 (N = 24) 3.0 (1.5) 1.1 (1.7) 8.3 (4.7) 7.5 (24.8)
Uncomplicated sepsis2 (N = 4) 3.6 (1.0) 1.7 (1.9) 11.5 (3.8) 0.4 (0.4)
Severe sepsis3 (N = 127) 3.9 (4.3) 3.0 (9.4) 9.0 (5.3) 6.5 (15.6)
Shock4 (N = 35) 4.8 (5.8) 5.5 (10.9) 15.5 (6.3) 20.7 (34.4)
Survivors (N = 190) 3.9 (4.3) 3.2 (9.1) 10.1 (5.9) 9.1 (21.9)
Non-survivors (N = 13) 3.9 (1.4) 5.0 (4.9) 17.5 (5.9) –
1SIRS (no infection with two or more of the following): 1 temp > 38.3 or < 36 °C, 2 heart rate > 90 bpm, 3 tachypnea resp. > 20 bpm or pCO2 < 32 mmHg, 4 WBC
< 4000mm3 or > 12,000mm3 or 10% bands
2Sepsis (infection with two or more of the aforementioned SIRS criteria)
3Severe sepsis: sepsis accompanied by organ dysfunction: 1 arterial hypotension (SAP < 90 mmHg, MAP < 70 mmHg), 2 reduced urine output (< 0.5 mL/kg/h for >
2 h); 3 acute lung injury (PaO2/FIO2 < 250 if without pneumonia or < 200 if afflicted with pneumonia) based on the ACCP/SCCM consensus document. The
following organ systems surveillance was available: cardiovascular, pulmonary, renal, and hematologic
4Septic shock: sepsis-induced hypotension persisting despite adequate fluid resuscitation
5There were only three subjects available in the non-survivor group in which the PCT level was available
6Significance between SIRS and sepsis (p = 0.009), SIRS and severe sepsis (p = 0.02), SIRS and septic shock (p = 0.01), and SIRS and death (p = 0.04)
No significance between survivors and non-survivors
7Significance between SIRS and septic shock (p = 0.012); between SIRS and death (p = 0.001); between severe sepsis and death (p = 0.003); between sepsis vice
SIRS (p = 0.036); between survivors and non-survivors (p = 0.007)
8Significance between SIRS and septic shock (p = 0.002); SIRS and severe sepsis (p < 0.002)
9Significance between SIRS and septic shock (p < 0.001); between SIRS and death (p < 0.001); between severe sepsis and septic shock and death (p < 0.001);
between SIRS and sepsis (p = 0.044); between survivors and non-survivors (p < 0.001)
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Biomarker correlations
Even though cfDNA and nucleosomes are both apop-
totic biomarkers, they may reflect different aspects of
that process. We therefore correlated concentrations of
these two biomarkers with each other. Furthermore,
these two apoptotic biomarkers may be co-linear or
complementary with other prognostic biomarkers, spe-
cifically PCT and APACHE II score. We therefore
also assessed correlations between cfDNA, nucleo-
somes, PCT, and APACHE II (Table 3). While there
was a modest correlation between cfDNA and nucleo-
somes (0.41), there was a smaller correlation between
cfDNA and PCT and APACHE II (0.29 and 0.21, re-
spectively). The nucleosome levels exhibited a simi-
larly low correlation with PCT and APACHE II (0.07
and 0.24, respectively).
Predicting 28-day mortality
Mortality prediction models using cfDNA (at T0), nucle-
osomes (at T0), or APACHE II (at T0) yielded AUC
values of 0.61, 0.75, and 0.81, respectively (Table 4). As
asserted in Table 2, there were too few subjects in our
cohort possessing PCT levels to provide meaningful in-
terpretation. Permutations of a mortality prediction tool
that used various combinations of cfDNA, nucleosomes,
and APACHE II revealed that only nucleosome concen-
trations added to the predictive accuracy of APACHE II
alone (0.84).
Discriminating SIRS from sepsis
Procalcitonin has been widely used as a sepsis diagnostic
biomarker. We therefore determined whether measuring
cfDNA or nucleosome improved the ability of procalci-
tonin to discriminate sepsis from SIRS. When used
alone, we observed similarly modest AUCs for both
cfDNA (0.62) and nucleosomes (0.63). When restricting
to the subset of subjects who had available PCT results
(n = 107), the AUC values for sepsis vs. SIRS discrimin-
ation were 0.64 for procalcitonin, 0.65 for cfDNA (at
T0), and 0.63 for nucleosomes (at T0). There was no sig-
nificant difference in the AUC for cfDNA and nucleo-
somes in the entire data set relative to the subset
providing procalcitonin. A model incorporating all three
biomarkers had an improved AUC of 0.74 (Table 5).
Discussion
Apoptosis is a well-recognized biological pathway in the
host’s response to infection [3, 13]. It is therefore
plausible that cfDNA and nucleosomes, both by-products
of the apoptosis pathway exhibiting biological roles (pri-
marily originating from lymphocytes and neutrophils),
could serve as useful sepsis biomarkers [29]. These bio-
markers are inextricably linked within the interdependent
innate and adaptive immunity (including NETosis),
modulating endothelial homeostasis, and biasing the deli-
cate balance within several pathways and their counter-
regulatory cascades (including inflammatory, coagulation,
Fig. 2 Nucleosome group means and standard deviations at T0 and T24. Gold (SIRS); blue (sepsis); green (severe sepsis); red (septic shock);
black (non-survivors)
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and fibrinolytic) [1, 26, 30]. It is not yet known if altering
cfDNA or nucleosome levels or their dynamics could in-
fluence the evolution and outcomes in sepsis. In this
study, we sought to answer a more proximal question,
which is whether cfDNA or nucleosomes correlated with
various aspects of sepsis such as diagnosis, severity, and
prognosis. Furthermore, we wished to assess how these
biomarkers compared with each other and what import-
ance might they serve when combined with other
sepsis-related biomarkers and predictive scores. As prior
studies suggested that the cfDNA level in sepsis patients
are primarily host derived (nuclear) in origin (not second-
ary to prokaryotic origins), we did not pursue a rigorous
delineation of the source of nucleic acid in this effort as
the major impetus was to seek a clinically relevant and re-
liable predictive diagnostic and prognostic biomarker
panel [3, 13].
The prognostic accuracy of cfDNA to predict
sepsis-mediated mortality was modest in this study (AUC
of 0.61) but is comparable to that reported in the literature
for non-ICU admitted subjects exhibiting AUCs (0.61 to
0.84) [3, 17, 22]. Notably, hitherto enrollment has been
restricted to severely septic patients admitted to the ICU
wherein the cfDNA exhibited superior prognostic accur-
acy (AUC of 0.7–0.97) [3, 13, 15, 17, 22, 27]. The lower
accuracy observed in our investigation may be attributed
to the (1) small sample size (and most saliently few sub-
jects experiencing mortality), (2) inclusion of less ill sepsis
patients irrespective of ICU admission, (3) possible sample
degradation from long-term storage (although speculative
should have been minimized exploiting our chosen assay),
(4) the pronounced intra and inter-individual variability in
cfDNA levels, (5) differential renal clearance, and (6) dif-
ferential comorbidities that likely contribute to poorer
predictive accuracy in patients experiencing less severe
sepsis (and non-infectious SIRS). Of note, we had too few
cases of specific clinical syndromes (comorbidities) and
most specifically renal insufficiency to control for and
evaluate their independent influence upon mortality and
certainly warrants attention in future investigations. Thus,
Fig. 3 cfDNA group means and standard deviations at T0 and T24. Gold (SIRS); blue (sepsis); green (severe sepsis); red (septic shock);
black (non-survivors)
Table 3 Correlation table
cfDNA Nucleosome PCT2 APACHE II
cfDNA 1 0.41 0.29 0.21
Nucleosome 1 0.07 0.24
PCT1 1 0.41
APACHE II 1
Spearman’s correlation coefficient
1PCT concentrations available for 107 patients
Table 4 AUC for predicting mortality
AUC for predicting mortality
Biomarker or APACHE II Scoring System AUC (N = 203)
predicting mortality
cfDNA (T0) 0.61 (0.46–0.75)
cfDNA (T24) 0.62 (0.47–0.76)
Nucleosome (T0) 0.75 (0.62–0.87)
Nucleosome (T24) 0.67 (0.52–0.81)
APACHE II (T0) 0.81 (0.69–0.93)
APACHE II (T0) + cfDNA (T0) 0.81 (0.70–0.93)
APACHE II (T0) + nucleosome (T0) 0.84 (0.72–0.96)
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cfDNA levels may be best exploited in severe sepsis patients
admitted to the ICU. Finally, of note, there have been no
significant differences in cfDNA levels observed relative to
the type of infecting organism [31].
The prognostic accuracy of nucleosomes for predicting
sepsis-associated mortality was higher than that pre-
dicted by cfDNA and more consistent with published lit-
erature [14, 19]. We observed a modest correlation
between these two biomarkers, which was less than ex-
pected given their shared biology. We speculate this may
attributed to (1) differential nucleosome and cfDNA
levels generated via variable apoptosis/necrosis ratios
and NETosis, (2) cfDNA encompassing non-nuclear
(mtDNA), (3) differential half-lives and clearance kinet-
ics of their components, and (4) variability introduced
by the assay method (ELISA) [1]. These observations
suggest that in addition to concerted attention to con-
sider potential representation in predictive biomarker
panels, multiple apoptotic biomarkers (cfDNA, mucleo-
somes, histones) may be considered.
Both cfDNA and nucleosome (the latter significantly)
were higher in non-survivors, but neither biomarker dis-
criminated sepsis severity among survivors consistent
with published data [3, 17, 18, 21, 22, 27, 32–35]. In-
creased levels among non-survivors may stem from a
discrete increase in immune cell destruction, and bias to
necrosis relative to caspase-dependent apoptosis in
non-survivors [1, 32]. This suggests a reproducible dichot-
omy in host molecular responses highlighting allostasis
(pathway normalization or compensation) in survivors
and maladaption (pathway dysregulation and funneling to
conserved death pathways) in non-survivors.
PCT is a host response biomarker that is secreted pri-
marily in the context of bacterial infection but can also
be elevated in certain non-infectious conditions. How-
ever, it is frequently used to help discriminate sepsis
from non-infectious conditions. Moreover, it is part of
the host’s inflammatory pathway and presumably
represents biology that is largely orthogonal to apop-
tosis. The subjects from which PCT was acquired may
have experienced clinical endpoints deviating systematic-
ally from the entire cohort. However, we did not identify
any systematic differences in demographics or salient
clinical parameters between these cohorts, as delineated
in Table 1. APACHE II is a commonly used clinical score
that incorporates a variety of host factors such as age,
comorbidity, and organ function assessments to create a
sepsis severity score which correlates with mortality. Re-
grettably, as intimated earlier, the CAPSOD investigation
experienced a lower percentage of non-survivors than
historical or contemporary reported sepsis-associated
mortality rates. Thus, we had too few non-survivors pos-
sessing PCT levels to pursue a mortality prediction
model. Given the poor correlation of these apoptotic
biomarkers with both PCT and the APACHE II, and the
known biology of apoptosis, we conjecture that apop-
totic biomarkers reflect an important septic pathway
non-collinear or not otherwise reflected in the APACHE
II or other biomarkers (PCT) and thus would be
complimentary to them, thus adding accuracy to the
mortality prediction model [3, 13]. We observed a mod-
est increase in the AUC (from 0.81 to 0.84) appending
nucleosomes to the APACHE II which although unlikely
to add clinically significant predictive prognostic dis-
crimination, we suspect that the additive predictive ac-
curacy of the apoptotic biomarkers was muted by the
unusually high predictive value of the APACHE II score
in this cohort secondary to the low numbers of
non-survivors.
The rates of non-infectious etiologies misdiagnosed as
sepsis are estimated to be 14–18% in the emergency de-
partment population [36]. Most biomarkers studied to
date are insensitive in differentiating SIRS stemming
from infectious or non-infectious etiologies [21]. Im-
provements in predictive diagnostic accuracy would ex-
pedite accurate diagnoses, promoting prompt and
appropriate therapeutic intervention and circumventing
unnecessary antibiotic exposure. Both apoptotic bio-
markers exhibited poor diagnostic accuracy to differenti-
ate SIRS from sepsis (we speculate due to dilution with
non-ICU admitted patients), yet was consistent with
prior literature (nucleosomes exhibited a diagnostic
AUC for discriminating sepsis in ICU patients of 0.7
[4]). However, we did observe a significant increase in
AUC (0.74) exploiting our three-parameter model dem-
onstrating independent and additive diagnostic predict-
ive power from the apoptosis pathways.
Serial testing of sepsis biomarkers (e.g., procalcitonin,
caspase, cleaved cytokeratin18, and protein C) may pro-
vide superior discriminatory power [3, 37]. However,
cfDNA may not be useful for serial monitoring since
concentrations remain stable for several days following
sepsis presentation suggesting a fixed burden of cumula-
tive tissue injury dictated by sepsis severity [3, 13, 17,
Table 5 AUC for diagnosis (differentiating SIRS from sepsis)
AUC (N = 203)
Predicting sepsis
cfDNA (T0) 0.62 (0.50–0.74)
Nucleosome (T0) 0.63 (0.52–0.73)
Subset of patients (N = 107) possessing PCT values
AUC (N = 107)
Predicting sepsis
Nucleosome (T0) 0.63 (0.46–0.79)
CfDNA (T0) 0.65 (0.44–0.85)
PCT (T0) 0.64 (0.49–0.79)
PCT (T0) + nucleosome (T0) + cfDNA (T0) 0.74 (0.60–0.88)
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37]. We corroborated these observations identifying
nonsignificant differences in the cfDNA levels in our in-
vestigation at T0 and T24. We acknowledge that the
“stationary” kinetics encompasses a dynamic of fluctuat-
ing nucleic acid derived from NETosis, apoptosis, necro-
sis, and endogenous DNase activity. Unlike the cfDNA
levels, we did identify significant elevation in the nucleo-
some levels from T0 to T24 (accompanied by increased
variability). However, we did not identify differential pre-
dictive value for diagnosis or prognosis at T24 from T0
(likely attributed to the wide variability). We are not
aware of any literature describing nucleosome kinetics;
thus, this is the first report revealing the increasing nu-
cleosome concentrations in septic patients in the first
24 h, which deviates from the stationary kinetics exhib-
ited by cfDNA. Given the relative dearth of research spe-
cific to nucleosomes in sepsis, further research is
necessary to define its kinetics and variability as a func-
tion of clinical state. Whereas biomarker dynamics pro-
vide useful information about a patient’s state of illness
and response to treatment, stable biomarkers can be
useful clinically as they may provide a reliable inference
as to the severity of sepsis at presentation (regardless of
its heterogeneity), although not informing changing clin-
ical states or treatment response.
Technology will need to be developed potentiating
real-time measurement of cfDNA or nucleosomes so
their relevance to clinical practice may be realized. Fu-
ture research may attempt partitioning the source of
cfDNA (mitochondrial, nuclear) and clarifying the pre-
dictive accuracy of the constituents of nucleosomes (his-
tones) which may provide further insight into
differentiating their relative propensity to promoting in-
flammation, coagulation, anti-fibrinolysis, antibacterial
activity, and predictive (diagnostic and prognostication)
power [2]. Alternative apoptotic biomarkers may be su-
perior in their discriminatory potential and targeted for
future research [31, 38]. Finally, all apoptotic biomarkers
would ideally be developed as a real-time point of care
testing platform.
Limitations
We employed a convenience sampling constrained by
subjects with definitive adjudicated diagnoses and who
had sufficient banked plasma for biomarker measure-
ments (although did not observe any significant system-
atic bias from the full cohort in terms of demographics
(age, gender), source of infection, infectious pathogen, or
representation across the various sepsis categories save
for uncomplicated sepsis). The low mortality in this co-
hort may have resulted in a lower sensitivity of these
biomarkers for severe disease. However, this did repre-
sent a more realistic cohort of patients with sepsis, not
all of whom are managed in the ICU. Long-term storage
may have led to differential cfDNA and nucleosome deg-
radation which is uncontrolled with the retrospective
analyses employed herein (however, we acknowledge the
cfDNA fluorometric assay employed circumvents con-
cerns in DNA fragmentation) [3]. Finally, samples
underwent one freeze-thaw cycle, however, again the
fluorometric assay circumvents concerns in DNA frag-
mentation, while nucleosome concentrations were
shown to remain stable through several freeze-thaw cy-
cles [25].
Conclusions
To our knowledge, this is the first head-to-head com-
parison of cfDNA and nucleosomes in diagnosing sepsis
and predicting sepsis-related mortality. Both cfDNA and
nucleosome concentrations demonstrated a modest abil-
ity to distinguish sepsis survivors and non-survivors and
provided additive diagnostic predictive accuracy in dif-
ferentiating sepsis from non-infectious SIRS when inte-
grated into a diagnostic prediction model including PCT
and APACHE II. A sepsis biomarker strategy incorporat-
ing measures of the apoptotic pathway may serve as an
important component of a sepsis diagnostic and mortal-
ity prediction tool.
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